B+
Bull case
35%
Probability
Target price
$14.00
+3.6% vs current
OGN
OrganonBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$13.30
-1.6% vs current
B-
Bear case
20%
Probability
Target price
$10.80
-20.1% vs current
AI sentiment snapshot
Latest data as of 2026-07-10
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.5
Score
AI commentary
Primary-source support is strong enough to keep the memo above purely tentative status, but the tone should remain cautious. Recent company news has been modestly positive around MIUDELLA, Tofidence, and VTAMA-related visibility, while the most recent operating update showed a soft quarter and suspended guidance/calls because of the pending merger. Coverage looks thinner than ideal, analyst-target support is below the current share price, and no usable social or options context was provided, so this still reads mainly as a monitoring-style merger-spread setup rather than a clean standalone bullish thesis.
RankAlpha Sentiment Codex - 2026-07-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30catalystMIUDELLA launch preparation adds a late-2026 women’s health offsetMedium impact
Organon’s June 22, 2026 company release said it completed the global licensing agreement for MIUDELLA and that the hormone-free IUD is anticipated to be commercially available in late 2026, giving Organon a new women’s health launch lever as legacy contraception demand remains pressured [#IR-2026-06-22].
2026-12-31catalystBiosimilars growth must keep offsetting erosion in core women’s health brandsMedium impact
First-quarter 2026 revenue fell 4% reported and 9% ex-FX, with Women’s Health down 19% ex-FX while Biosimilars grew 21% ex-FX, helped by Hadlima demand and newer assets; if the merger timeline stretches, investors will keep testing whether biosimilars and recent label-expansion assets can offset ongoing weakness in Nexplanon, oral contraceptives, and parts of Established Brands [#SEC-8K-2026-04-30].
2027-03-31eventPending Sun Pharma transaction remains the main valuation anchorMedium impact
Organon said on April 30, 2026 that its pending merger with Sun Pharmaceutical Industries is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval; with management also suspending guidance and earnings calls during the process, the stock still trades mainly on deal-close confidence rather than a standalone re-rating [#SEC-8K-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-10 • Updated nightlySource: Internal modelMethodology